Being Precise About Precision Medicine: What Should Value Frameworks Incorporate to Address Precision Medicine? A Report of the Personalized Precision Medicine Special Interest Group

被引:65
作者
Faulkner, Eric [1 ,2 ,3 ]
Holtorf, Anke-Peggy [4 ]
Walton, Surrey [5 ,6 ]
Liu, Christine Y. [7 ]
Lin, Hwee [8 ]
Biltaj, Eman [9 ]
Brixner, Diana [9 ]
Barr, Charles [10 ]
Oberg, Jennifer [11 ]
Shandhu, Gurmit [12 ]
Siebert, Uwe [13 ,14 ,15 ,16 ]
Snyder, Susan R. [17 ]
Tiwana, Simran [18 ]
Watkins, John [19 ]
Ijzerman, Maarten J. [20 ]
Payne, Katherine [21 ]
机构
[1] Evidera, Bethesda, MD USA
[2] Univ N Carolina, Chapel Hill, NC 27515 USA
[3] Natl Assoc Managed Care Phys, Glen Allen, VA USA
[4] Hlth Outcomes Strategies, Basel, Switzerland
[5] Univ Illinois, Chicago, IL USA
[6] Second City Outcomes Res LLC, Chicago, IL USA
[7] Methodist Hlth Syst, Richardson, TX USA
[8] Natl Univ Singapore, Singapore, Singapore
[9] Univ Utah, Salt Lake City, UT USA
[10] Strateg Consulting, San Francisco, CA USA
[11] Columbia Univ, New York, NY USA
[12] Gurmit Shandhu Consulting GMBH, Basel, Switzerland
[13] Univ Hlth Sci Med Informat & Technol, Hall In Tirol, Austria
[14] Harvard Sch Publ Hlth, Boston, MA USA
[15] Harvard Med Sch, Boston, MA 02115 USA
[16] ONCOTYROL Ctr Personalized Canc Med, Innsbruck, Austria
[17] Georgia State Univ, Atlanta, GA 30303 USA
[18] Amgen Inc, Thousand Oaks, CA 91320 USA
[19] Premera Blue Cross, Mountlake Terrace, WA USA
[20] Univ Melbourne, Ctr Canc Res, Parkville, Vic, Australia
[21] Univ Manchester, Manchester, Lancs, England
关键词
precision medicine and diagnostics; health technology assessment; value frameworks; HEALTH ECONOMICS APPROACH; TECHNOLOGY-ASSESSMENT; COST-EFFECTIVENESS; DECISION-MAKING; CHALLENGES; PATIENT; THERAPIES; SOCIETY; IMPACT;
D O I
10.1016/j.jval.2019.11.010
中图分类号
F [经济];
学科分类号
02 ;
摘要
Precision medicine is a dynamic area embracing a diverse and increasing type of approaches that allow the targeting of new medicines, screening programs or preventive healthcare strategies, which include the use of biologic markers or complex tests driven by algorithms also potentially taking account of patient preferences. The International Society for Pharmacoeconomics and Outcome Research expanded its current work around precision medicine to (1) describe the evolving paradigm of precision medicine with examples of current and evolving applications, (2) describe key stakeholders perspectives on the value of precision medicine in their respective domains, and (3) define the core factors that should be considered in a value assessment framework for precision medicine. With the ultimate goal of improving health of well-defined patient groups, precision medicine will affect all stakeholders in the healthcare system at multiple levels spanning the individual perspective to the societal perspective. For an efficient, timely and practical precision medicine value assessment framework, it will be important to address these multiple perspectives through building consensus among the stakeholders for robust procedures and measures of value aspects, including performance of precision mechanism; aligned reimbursement processes of precision mechanism and subsequent treatment; transparent expectations for evidence requirements and study designs adequately matched to the intended use of the precision mechanism and to the smaller target patient populations; recognizing the potential range of value-generation such as ruling-in and ruling-out decisions.
引用
收藏
页码:529 / 539
页数:11
相关论文
共 98 条
[91]   What is personalized medicine: sharpening a vague term based on a systematic literature review [J].
Schleidgen, Sebastian ;
Klingler, Corinna ;
Bertram, Teresa ;
Rogowski, Wolf H. ;
Marckmann, Georg .
BMC MEDICAL ETHICS, 2013, 14
[92]   American Society of Clinical Oncology Statement: A Conceptual Framework to Assess the Value of Cancer Treatment Options [J].
Schnipper, Lowell E. ;
Davidson, Nancy E. ;
Wollins, Dana S. ;
Tyne, Courtney ;
Blayney, Douglas W. ;
Blum, Diane ;
Dicker, Adam P. ;
Ganz, Patricia A. ;
Hoverman, J. Russell ;
Langdon, Robert ;
Lyman, Gary H. ;
Meropol, Neal J. ;
Mulvey, Therese ;
Newcomer, Lee ;
Peppercorn, Jeffrey ;
Polite, Blase ;
Raghavan, Derek ;
Rossi, Gregory ;
Saltz, Leonard ;
Schrag, Deborah ;
Smith, Thomas J. ;
Yu, Peter P. ;
Hudis, Clifford A. ;
Schilsky, Richard L. .
JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (23) :2563-U132
[93]   Economic evaluations of personalized medicine: existing challenges and current developments [J].
Shabaruddin, Fatiha H. ;
Fleeman, Nigel D. ;
Payne, Katherine .
PHARMACOGENOMICS & PERSONALIZED MEDICINE, 2015, 8 :115-126
[94]   Adjuvant Chemotherapy Guided by a 21-Gene Expression Assay in Breast Cancer [J].
Sparano, J. A. ;
Gray, R. J. ;
Makower, D. F. ;
Pritchard, K. I. ;
Albain, K. S. ;
Hayes, D. F. ;
Geyer, C. E., Jr. ;
Dees, E. C. ;
Goetz, M. P. ;
Olson, J. A., Jr. ;
Lively, T. ;
Badve, S. S. ;
Saphner, T. J. ;
Wagner, L. I. ;
Whelan, T. J. ;
Ellis, M. J. ;
Paik, S. ;
Wood, W. C. ;
Ravdin, P. M. ;
Keane, M. M. ;
Moreno, H. L. Gomez ;
Reddy, P. S. ;
Goggins, T. F. ;
Mayer, I. A. ;
Brufsky, A. M. ;
Toppmeyer, D. L. ;
Kaklamani, V. G. ;
Berenberg, J. L. ;
Abrams, J. ;
Sledge, G. W., Jr. .
NEW ENGLAND JOURNAL OF MEDICINE, 2018, 379 (02) :111-121
[95]   Validation, updating and impact of clinical prediction rules: A review [J].
Toll, D. B. ;
Janssen, K. J. M. ;
Vergouwe, Y. ;
Moons, K. G. M. .
JOURNAL OF CLINICAL EPIDEMIOLOGY, 2008, 61 (11) :1085-1094
[96]  
Towse A, 2017, J Cancer Policy, V11, P48, DOI 10.1016/j.jcpo.2016.09.003
[97]   Stratified medicine: strategic and economic implications of combining drugs and clinical biomarkers [J].
Trusheim, Mark R. ;
Berndt, Ernst R. ;
Douglas, Frank L. .
NATURE REVIEWS DRUG DISCOVERY, 2007, 6 (04) :287-293
[98]   Review of Recent US Value Frameworks-A Health Economics Approach: An ISPOR Special Task Force Report [6] [J].
Willke, Richard J. ;
Neumann, Peter J. ;
Garrison, Louis P., Jr. ;
Ramsey, Scott D. .
VALUE IN HEALTH, 2018, 21 (02) :155-160